Osimertinib May Be an Effective First-Line Therapy in EGFR-Mutant NSCLC [Clinical Trials]

Osimertinib achieved objective responses in 77% of patients with treatment-naïve NSCLC.

from Cancer via ola Kala on Inoreader http://ift.tt/2yTpqWP
via IFTTT